Comparable stake leader
TAKEDA PHARMACEUTICAL CO LTD
SEC ownership of Theseus Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001745020.
Disclosed value leader
TAKEDA PHARMACEUTICAL CO LTD
Comparable rows
0/11
Latest evidence
14 Feb 2024
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
TAKEDA PHARMACEUTICAL CO LTD
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
14 Feb 2024
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001745020
- Issuer location
- Cambridge, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Theseus Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TAKEDA PHARMACEUTICAL CO LTD
Disclosed value leader
TAKEDA PHARMACEUTICAL CO LTD
Comparable rows
0/11
Latest evidence
14 Feb 2024
3/4/5
Highest disclosed value: $4,927,052
11 rows are not safely comparable across share classes.
Showing 1-8 of 11 holder rows.
Quick read
TAKEDA PHARMACEUTICAL CO LTD has the largest disclosed position value at $4.93M.
0 of 11 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TAKEDA PHARMACEUTICAL CO LTD's linked filing trail.
Disclosed position value
Top 5
TAKEDA PHARMACEUTICAL CO LTD
$4.93M
Foresite Capital Management V, LLC
$4.23M
Omega Fund VI, L.P.
$2.17M
Rock Springs Capital Management LP
$1.83M
William Shakespeare
$2.02M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 11 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTD |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$4,927,052
1,615,427 shares
|
— | 12 Oct 2021 |
| Foresite Capital Management V, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$4,226,766
1,385,825 shares
|
— | 17 Jul 2023 |
| Omega Fund VI, L.P. |
3/4/5
Former 10% owner
|
—
class O/S missing
|
$2,170,011
711,479 shares
|
— | 12 Oct 2021 |
| Rock Springs Capital Management LP |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$1,827,926
599,320 shares
|
— | 12 Oct 2021 |
| William Shakespeare |
3/4/5
President of Research and Development
|
—
mixed-class rows
|
$2,015,007
753,918 shares
mixed-class rows
|
— | 06 Nov 2023 |
| Timothy P. Clackson |
3/4/5
President and CEO, Director
|
—
mixed-class rows
|
$139,156
319,375 shares
mixed-class rows
|
— | 01 Mar 2023 |
| David Kerstein |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
$53,375
17,500 shares
|
— | 01 Mar 2023 |
| Victor Rivera |
3/4/5
Chief Scientific Officer
|
—
class O/S missing
|
$49,563
16,250 shares
|
— | 01 Mar 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Oct 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Theseus Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
TAKEDA PHARMACEUTICAL CO LTD
Net 12M change
$0
Latest report
14 Feb 2024
Recent insider transactions for Theseus Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.